ClinicalTrials.gg

Program

bitopertin

Also written as “RO4917838”, “bitopertin [RO4917838]” and “DISC-1459”.

Its studies are mostly in Schizophrenia · Protoporphyria, Erythropoietic · beta-Thalassemia · Obsessive-Compulsive Disorder, led by 2 companies.

Furthest: phase 3, since Aug 30, 201026 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche230 open or runningphase 3since Aug 30, 2010Feb 4, 2008none ahead
Disc Medicine31 open or runningphase 3since May 22, 2023Mar 21, 2022Jun 2028phase 3 · NCT05883748

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Feb 4, 2008.

  1. Aug 31, 2011Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01433575 · 16 enrolled · China
  2. Sep 21, 2011Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01438749 · 177 enrolled · United States
  3. Dec 15, 2011Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01495104 · 18 enrolled · France
  4. Jan 12, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01510899 · 12 enrolled · France, Russian Federation
  5. Feb 28, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01543529 · 25 enrolled · France
  6. May 23, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01613040 · 169 enrolled · United States, France
  7. Jul 6, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01636492 · 71 enrolled · New Zealand
  8. Aug 14, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01665976 · 16 enrolled · France
  9. Aug 15, 2012Phase 2 study in Obsessive-Compulsive DisorderHoffmann-La Roche · NCT01674361 · 99 enrolled · United States, Canada
  10. Dec 18, 2013Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02019290
  11. Sep 1, 2017Phase 2 study in beta-ThalassemiaHoffmann-La Roche · NCT03271541 · 12 enrolled · Italy, Lebanon, Thailand
  12. Mar 21, 2022Disc Medicine's first study: phase 2 study in Protoporphyria, ErythropoieticNew to Disc MedicineDisc Medicine · NCT05308472 · 75 enrolled · United States
  13. May 22, 2023Phase 3 study in Protoporphyria, ErythropoieticDisc Medicine · NCT05883748 · 230 planned · United States, Australia, Belgium and more
  14. Mar 17, 2025Phase 3 study in Protoporphyria, ErythropoieticDisc Medicine · NCT06910358 · 183 enrolled · United States, Australia, Belgium and more

Ahead

  1. Jun 2028Primary completion: phase 3 study in Protoporphyria, ErythropoieticDisc Medicine · NCT05883748

TargetBeta

SLC6A9 →read by rule
“Glycine transporter 1 inhibitor”ChEMBL 37, by rule

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06910358Protoporphyria, Erythropoietic · United States, Australia, Belgium and more3CompletedDisc MedicineSep 8, 2026183
NCT05883748Protoporphyria, Erythropoietic · United States, Australia, Belgium and more3By invitationDisc MedicineJun 2028230
NCT05308472Protoporphyria, Erythropoietic · United States2CompletedDisc MedicineFeb 20, 202475
NCT03271541beta-Thalassemia · Italy, Lebanon, Thailand2CompletedHoffmann-La RocheJun 29, 201812
NCT02019290Healthy Volunteer1WithdrawnHoffmann-La RocheMar 31, 20140
NCT01674361Obsessive-Compulsive Disorder · United States, Canada2CompletedHoffmann-La RocheApr 30, 201599
NCT01665976Healthy Volunteer · France1CompletedHoffmann-La RocheNov 201216
NCT01636492Healthy Volunteer · New Zealand1CompletedHoffmann-La RocheAug 200671
NCT01613040Healthy Volunteer · United States, France1CompletedHoffmann-La RocheJul 2009169
NCT01543529Healthy Volunteer · France1CompletedHoffmann-La RocheJun 4, 201225
NCT01510899Healthy Volunteer · France, Russian Federation1CompletedHoffmann-La RocheMar 201212
NCT01495104Healthy Volunteer · France1CompletedHoffmann-La RocheJan 201218
NCT01438749Healthy Volunteer · United States1CompletedHoffmann-La RocheMay 2012177
NCT01433575Healthy Volunteer · China1CompletedHoffmann-La RocheNov 201116
NCT01365403Healthy Volunteer · France1CompletedHoffmann-La RocheJul 201116
NCT01356550Healthy Volunteer · France, Russian Federation1CompletedHoffmann-La RocheOct 201135
NCT01234779Schizophrenia · United States, Romania, Russian Federation and more2CompletedHoffmann-La RocheSep 2012301
NCT01235585Schizophrenia · United States, Brazil, Canada and more3CompletedHoffmann-La RocheSep 2014597
NCT01235559Schizophrenia · United States, Bulgaria, China and more3CompletedHoffmann-La RocheMar 2015604
NCT01235520Schizophrenia · United States, Argentina, Australia and more3CompletedHoffmann-La RocheJul 2014595
NCT01192906Schizophrenia · United States, Brazil, Canada and more3CompletedHoffmann-La RocheJul 2014624
NCT01192880Schizophrenia · United States, Bulgaria, China and more3CompletedHoffmann-La RocheJul 2014625
NCT01192867Schizophrenia · United States, Argentina, Australia and more3CompletedHoffmann-La RocheMay 26, 2014629
NCT01183585Healthy Volunteer · France1CompletedHoffmann-La RocheSep 201018
NCT01116830Schizophrenia · United States1CompletedHoffmann-La RocheFeb 201429
NCT00616798Schizophrenia · United States, Austria, Brazil and more2CompletedHoffmann-La RocheFeb 2010323

How it is read

Names in the registry

  • “RO4917838”, 20 entries
  • “bitopertin [RO4917838]”, 6 entries
  • “DISC-1459”, 5 entries
  • “Bitopertin”, 3 entries
  • “bitopertin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.